Industry News

Kollodis BioSciences Inc. Commercializes Recombinant Mussel Adhesive Proteins Using Its Patent-Protected MAPTrix™ Technology- A Global First.

Published on 2009-10-14. Author : SpecialChem

Seoul, Korea -- Kollodis BioSciences, Inc. has announced the launch of its recombinant mussel adhesive and MAPTrix® ECM line of products for cell culture and related applications. The Mussel Adhesive Protein based matrix (MAPTrix®) ECM line of products are coating reagents with genetically incorporated bioactive peptides (recognition peptides) which mimic the extracellular matrix (ECM) activity of collagen, fibronectin, laminin, and vitronectin proteins. The bioactive peptide mimics the extracellular matrix (ECM) protein and provides for cell attachment, spreading and growth. The mussel adhesive protein confers biocompatible adhesion to a wide variety of surfaces.

The MAPTrix® ECM line of coating products provide an "in vivo like" environment for cell culture and tissue engineering applications. Unlike the conventional chemistry approach of peptide synthesis/immobilization, MAPTrix® coatings provide a simple, convenient and highly reproducible method for engineering a tailored ECM surfaces that bind adhesion receptors and promote cell adhesion. The products can be used in cell culture applications alone or in combination with other products. They are soluble in a variety of buffers under a wide range of pH conditions.

Features and benefits of the MAPTrix® ECM line of products include:
  • Animal-protein free, E. coli- protein free, toxic chemical free, biocompatible
  • Ready-to-use aqeuous coating formulations that save time and money
  • Fully compatible with existing standard protocols
  • Coats and adheres to a wide variety of surfaces including glass, plastic and biological surfaces
  • Promotes cell plating efficiency, improved cell morphology, and enhanced cell proliferation
  • Serum-free and low-serum cell culture applications
  • Quality manufactured and performance tested in accordance with ISO/USP guidelines.

MAPTrix® products are provided as ready-to-use aqueous coating formulations in 1.0 mg, 2.5 mg, 5.0 mg and 10.0 mg sizes (vials). Also available is our MAPTrix® core product - recombinant mussel adhesive protein with no peptide incorporation. The products are available through select distributors and directly from the company.

About Kollodis BioSciences, Inc.

Kollodis BioSciences, Inc. has successfully developed a proprietary recombinant protein expression system for the large scale production of various mussel adhesive proteins (MAP). Kollodis is developing MAP-based smart biomaterials for biotech, medical and industrial applications. The Company's proprietary and patented MAPTrix™ platform technology recombinantly incorporates bioactive peptides into a mussel adhesive protein (MAP) for cell culture and related applications.

Source: Kollodis BioSciences

The Chemicals Sales & Marketing Toolbox
Back to Top